Neuronata

CorestemChemon is a South Korean biotechnology company specializing in the development of stem cell therapies for rare and incurable diseases. The company is best known for Neuronata-R, the world's first autologous stem cell therapy approved for the treatment of Amyotrophic Lateral Sclerosis (ALS), which received conditional marketing authorization in South Korea. CorestemChemon operates a robust R&D pipeline focusing on various neurological and autoimmune conditions, utilizing its proprietary mesenchymal stem cell technology. In 2022, Corestem merged with Chemon, a leading contract research organization (CRO), to integrate drug development and testing capabilities. The company is currently conducting global Phase 3 clinical trials for Neuronata-R to expand its regulatory reach into the United States and European markets.